Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away

Corcept Therapeutics (CORT) crashed on Dec. 31 after the Food and Drug Administration (FDA) rejected its application for relacorilant, its investigational treatment for Cushing’s syndrome. 

The agency’s Complete Response Letter cited insufficient data for conducting a favorable benefit-risk assessment, requiring additional evidence of effectiveness for the hypertension treatment in patients with hypercortisolism. 

Fundamentals

See More
  • Market Capitalization, $K 1,302,503
  • Shares Outstanding, K 165,924
  • Annual Sales, $ 203,070 K
  • Annual Income, $ -54,840 K
  • EBIT $ 21 M
  • EBITDA $ 36 M
  • 60-Month Beta 0.57
  • Price/Sales 5.97
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 87.77% (-26.73%)
  • Historical Volatility 51.27%
  • IV Percentile 56%
  • IV Rank 29.23%
  • IV High 185.97% on 04/08/25
  • IV Low 47.20% on 09/17/25
  • Expected Move (DTE 14) 0.79 (10.83%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 612
  • Volume Avg (30-Day) 536
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 16,446
  • Open Int (30-Day) 14,308
  • Expected Range 6.51 to 8.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.03
  • Number of Estimates 4
  • High Estimate 0.09
  • Low Estimate 0.00
  • Prior Year -0.03
  • Growth Rate Est. (year over year) +200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.47 +12.91%
on 12/05/25
8.22 -11.13%
on 12/31/25
+0.84 (+12.91%)
since 12/02/25
3-Month
6.47 +12.91%
on 12/05/25
10.08 -27.53%
on 11/05/25
-1.01 (-12.09%)
since 10/02/25
52-Week
3.14 +132.64%
on 01/13/25
10.08 -27.53%
on 11/05/25
+3.84 (+111.13%)
since 01/02/25

Most Recent Stories

More News
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away

Corcept shares crash as the FDA rejects its application for relacorilant. But is it worth buying CORT stock on the pullback?

CORT : 37.44 (+7.59%)
XERS : 7.39 (-5.86%)
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 7.39 (-5.86%)
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to $285-$290 million; previously $280-$290...

XERS : 7.39 (-5.86%)
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

Conference Call to be Held at 8:30 a.m. ET

XERS : 7.39 (-5.86%)
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 7.39 (-5.86%)
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Recorlev now holds four Orange Book-listed patents to 2040

XERS : 7.39 (-5.86%)
Xeris Biopharma: Q2 Earnings Snapshot

Xeris Biopharma: Q2 Earnings Snapshot

XERS : 7.39 (-5.86%)
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275...

XERS : 7.39 (-5.86%)
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 7.39 (-5.86%)
Xeris Biopharma: Q1 Earnings Snapshot

Xeris Biopharma: Q1 Earnings Snapshot

XERS : 7.39 (-5.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and...

See More

Key Turning Points

3rd Resistance Point 8.87
2nd Resistance Point 8.54
1st Resistance Point 8.20
Last Price 7.39
1st Support Level 7.53
2nd Support Level 7.20
3rd Support Level 6.86

See More

52-Week High 10.08
Fibonacci 61.8% 7.43
Last Price 7.39
Fibonacci 50% 6.61
Fibonacci 38.2% 5.79
52-Week Low 3.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar